complement-c3

POT-4 acetate inhibits Complement C3 activation. POT-4 acetate can be used for studies about age-related macular degeneration.

Compstatin control peptide acetate is a negative control of Compstatin. Compstatin is an inhibitor of complement protein C3 by binding and inhibiting the cleavage of complement C3.

AMY-101 acetate (Cp40 acetate) is a cyclic peptide, an inhibitor of C3 Complement and an immunomodulator used in the treatment of gingivitis and periodontitis, which significantly reduces inflammation and lowers MMP-8 and MMP-9 levels.AMY-101 acetate also have a palliative effect on covid -19-induced lung inflammation/injury and SARS-COV-2-related acute kidney injury in patients with acute respiratory distress syndrome (ARDS).

Compstatin TFA, a potent inhibitor of the complement system C3 characterized by species specificity, is a 13-residue cyclic peptide. It selectively binds to baboon C3 and demonstrates resistance to proteolytic cleavage in baboon blood (similar to humans), effectively inhibiting the activation of the primate complement system. Notably, Compstatin TFA exhibits IC 50 values of 63 μM and 12 μM for the classical and alternative complement pathways, respectively [1] [2] [3].

POT-4 TFA (AL-78898A TFA), a derivative of Compstatin, efficiently inhibits the activation of complement factor C3 and is utilized in research related to age-related macular degeneration [1] [2].

Compstatin is a cyclic peptide consisting of 13 amino acid residues and is a potent inhibitor of complement system C3. Compstatin is species-specific and has inhibitory effects only on the complement system of primates. Studies have shown that it can bind to baboon C3 and is resistant to proteolytic cleavage in baboon blood. Its IC50 values for the classical pathway and alternative pathway are 63 μM and 12 μM, respectively.

AMY-101 is a peptidic inhibitor of the central complement component C3 (KD: 0.5 nM). AMY-101 shows a favorable anti-inflammatory activity in models with COVID-19 severe pneumonia with systemic hyper inflammation.

AMY-101 TFA is a cyclic peptide that acts as an inhibitor of complement C3 and an immunomodulator, used for the treatment of gingivitis and periodontitis. It significantly reduces inflammation and lowers levels of MMP-8 and MMP-9. AMY-101 TFA also has a mitigating effect on lung inflammation/damage in patients with COVID-19-induced ARDS and acute kidney injury associated with SARS-CoV-2.

Boc-Leu-Gly-Arg-AMC is a specific fluorogenic substrate designed for the enzymatic detection and quantification of complement component C3/C5 convertases, coagulation factor Xa, and soybean trypsin-like enzyme activity. Boc-Leu-Gly-Arg-AMC is also susceptible to hydrolysis by macropain, a high molecular weight thiol proteinase isolated from human erythrocytes, making it a versatile tool for enzymatic assays.